EA201400002A1 - Способы лечения заболеваний сетчатки - Google Patents

Способы лечения заболеваний сетчатки

Info

Publication number
EA201400002A1
EA201400002A1 EA201400002A EA201400002A EA201400002A1 EA 201400002 A1 EA201400002 A1 EA 201400002A1 EA 201400002 A EA201400002 A EA 201400002A EA 201400002 A EA201400002 A EA 201400002A EA 201400002 A1 EA201400002 A1 EA 201400002A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
neurotrophic factor
retail
methods
treat diseases
Prior art date
Application number
EA201400002A
Other languages
English (en)
Inventor
Ронг Вен
Original Assignee
Юниверсити Оф Майами
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Майами filed Critical Юниверсити Оф Майами
Publication of EA201400002A1 publication Critical patent/EA201400002A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение предусматривает способы лечения заболевания сетчатки, включающие введение эффективного количества нейротрофического фактора субъекту с заболеванием сетчатки. Нейротрофические факторы, применимые в настоящем изобретении, включают мезэнцефалический астроцитарный нейротрофический фактор (MANF) и консервативный допаминовый нейротрофический фактор (CDNF). Настоящее изобретение дополнительно включает фармацевтические композиции и наборы, содержащие MANF и CDNF.
EA201400002A 2011-06-09 2012-06-08 Способы лечения заболеваний сетчатки EA201400002A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495182P 2011-06-09 2011-06-09
PCT/US2012/041701 WO2012170918A2 (en) 2011-06-09 2012-06-08 Methods of treatment for retinal diseases

Publications (1)

Publication Number Publication Date
EA201400002A1 true EA201400002A1 (ru) 2014-08-29

Family

ID=47296781

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400002A EA201400002A1 (ru) 2011-06-09 2012-06-08 Способы лечения заболеваний сетчатки

Country Status (12)

Country Link
US (2) US20140243264A1 (ru)
EP (1) EP2717903B1 (ru)
JP (1) JP6258197B2 (ru)
KR (1) KR20140063565A (ru)
CN (1) CN103987400B (ru)
AU (1) AU2012267519A1 (ru)
BR (1) BR112013031652A2 (ru)
CA (1) CA2838818A1 (ru)
EA (1) EA201400002A1 (ru)
ES (1) ES2594605T3 (ru)
WO (1) WO2012170918A2 (ru)
ZA (1) ZA201309557B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1373502B8 (en) 2001-03-20 2010-12-22 Amarantus Therapeutics, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
US20110212055A1 (en) * 2008-03-25 2011-09-01 Commissiong John W Neurodegenerative disorders
AU2012267519A1 (en) 2011-06-09 2014-01-09 University Of Miami Methods of treatment for retinal diseases
JP2017508793A (ja) * 2014-03-05 2017-03-30 シュワルツ、ローレンス エム.SCHWARTZ, Lawrence M. 感覚細胞を保護するための方法及び組成物
US20170252403A1 (en) * 2014-10-06 2017-09-07 Amarantus Bioscience Holdings, Inc. Methods and compositions for treating retinal disorders
CN107149673A (zh) * 2017-05-18 2017-09-12 山东大学 神经营养因子cdnf在制备缺血性脑血管疾病药物中的应用
EP4678236A3 (en) 2018-03-29 2026-04-08 MyNeuroCure Oy C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
CN110499330A (zh) * 2018-05-16 2019-11-26 上海市同济医院 重组腺相关病毒载体及其应用
CN108925783B (zh) * 2018-07-23 2021-09-21 浙江大学 烟粉虱manf基因或其表达的蛋白作为靶点在制备防治烟粉虱的药物中的应用
EP3829598A4 (en) * 2018-08-01 2022-06-29 Nanoneuron Therapeutics, Inc. Neuroprotective compositions and use thereof
DE102019123659A1 (de) 2019-09-04 2021-03-04 Sick Ag Verfahren zum Erstellen einer Karte, Verfahren zum Ermitteln einer Pose eines Fahrzeugs, Kartierungsvorrichtungen und Lokalisierungsvorrichtungen
EP3838912A1 (en) * 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
CN111317814B (zh) * 2020-04-23 2020-12-18 中国中医科学院眼科医院 一种冰片联合神经营养因子组合物及应用
CN119215182B (zh) * 2024-08-23 2025-09-05 安徽医科大学 一种口服结肠靶向硅纳米药物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612012A (en) 1982-07-28 1986-09-16 White Thomas C Corneal implant
FR2744013B1 (fr) 1996-01-30 1998-04-24 Corneal Ind Dispositif de keratoprothese
ES2262317T3 (es) * 1998-03-23 2006-11-16 Genentech, Inc. Gfr-alfa3 y sus usos.
WO2001070158A1 (en) 1998-08-27 2001-09-27 Weyerhaeuser Company Absorbent composite having surface dryness
CA2403804A1 (en) * 2000-03-21 2001-09-27 Curagen Corporation Vegf-modulated genes and methods employing them
EP1368468A4 (en) 2001-02-23 2005-02-16 Human Genome Sciences Inc HUMAN SEMINAR PROTEINS
EP1373502B8 (en) * 2001-03-20 2010-12-22 Amarantus Therapeutics, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
US20050177231A1 (en) 2001-09-10 2005-08-11 Ricci John L. Intra-ocular implant promoting direction guided cell growth
US7503155B2 (en) * 2002-08-26 2009-03-17 Meyers John G Method for packaging a tape substrate
US20060195915A1 (en) * 2002-08-30 2006-08-31 Licentia Ltd. Novel neurotrophic factor protein and uses thereof
US7452969B2 (en) * 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US7223275B2 (en) 2003-05-27 2007-05-29 Yichieh Shiuey System for cutting the cornea of an eye
US20050261234A1 (en) * 2004-04-22 2005-11-24 Florida Atlantic University GFAP-based gene therapy for treatment of retinal diseases
US9999497B2 (en) 2005-01-31 2018-06-19 Yichieh Shiuey Corneal implants and methods and systems for placement
US8868177B2 (en) * 2009-03-20 2014-10-21 ElectroCore, LLC Non-invasive treatment of neurodegenerative diseases
AU2005339101B2 (en) * 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
US20110212055A1 (en) * 2008-03-25 2011-09-01 Commissiong John W Neurodegenerative disorders
FI20080326A0 (fi) * 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US8109997B2 (en) 2009-01-18 2012-02-07 Eyeon Medical Ltd. Hydrophobic pseudo-endothelial implants for treating corneal edema
US9127083B2 (en) * 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
BR112012009801A8 (pt) * 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
WO2012004291A1 (en) * 2010-07-06 2012-01-12 Nanologica Ab Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients.
AU2012267519A1 (en) 2011-06-09 2014-01-09 University Of Miami Methods of treatment for retinal diseases
US20140094413A1 (en) * 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents

Also Published As

Publication number Publication date
US20180028607A1 (en) 2018-02-01
US20140243264A1 (en) 2014-08-28
WO2012170918A2 (en) 2012-12-13
WO2012170918A3 (en) 2014-05-08
ZA201309557B (en) 2015-05-27
CN103987400B (zh) 2019-09-13
US10195251B2 (en) 2019-02-05
JP2014518204A (ja) 2014-07-28
CA2838818A1 (en) 2012-12-13
BR112013031652A2 (pt) 2019-09-24
CN103987400A (zh) 2014-08-13
KR20140063565A (ko) 2014-05-27
JP6258197B2 (ja) 2018-01-17
AU2012267519A1 (en) 2014-01-09
ES2594605T3 (es) 2016-12-21
EP2717903A2 (en) 2014-04-16
EP2717903A4 (en) 2015-04-29
EP2717903B1 (en) 2016-08-10
NZ618743A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
WO2012170918A3 (en) Methods of treatment for retinal diseases
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
EA201370230A1 (ru) Новые ингибиторы rock
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
IN2015DN00450A (ru)
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
AU2011328009A8 (en) Compounds and methods for treating pain
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
IN2015DN00376A (ru)
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201300131A1 (ru) Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями
MX352772B (es) Composición y método para el diagnóstico y tratamiento de enfermedades asociadas con la degeneración de neuritas.
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом